Chronic kidney disease in the context of multimorbidity patterns: the role of physical performance

The screening for CKD among older people across Europe (SCOPE) study

Andrea Corsonello1,2, Paolo Fabbietti2*, Francesc Formiga3, Rafael Moreno-Gonzalez3, Lisanne Tap4, Francesco Mattace-Raso4, Regina Roller-Wirnsberger5, Gerhard Wirnsberger5, Johan Ärnlöv6,7,8, Axel C. Carlsson6,8, Christian Weingart3, Ellen Freiberger10, Tomasz Kostka11, Agnieszka Guliowska11, Pedro Gil12, Sara Lainez Martinez12, Itshak Melzer13, Ilan Yehoshua14, Fabrizia Lattanzio1 and on behalf of SCOPE investigators

Abstract

Background: Chronic kidney disease (CKD) is known to be associated with several co-occurring conditions. We aimed at exploring multimorbidity patterns associated with CKD, as well as the impact of physical performance and CKD severity on them in a population of older outpatients.

Methods: Our series consisted of 2252 patients enrolled in the Screening of CKD among Older People across Europe multicenter observational study. Hypertension, stroke, transient ischemic attack, cancer, hip fracture, osteoporosis, Parkinson’s disease, asthma, chronic obstructive pulmonary disease, congestive heart failure, angina, myocardial infarction, atrial fibrillation, anemia, CKD (defined as GFR < 60, < 45 or < 30 ml/min/1.73 m²), cognitive impairment, depression, hearing impairment and vision impairment were included in the analyses. Physical performance was assessed by the Short Physical Performance Battery (SPPB) and used as stratification variable. Pairs of co-occurring diseases were analyzed by logistic regression. Patterns of multimorbidity were investigated by hierarchical cluster analysis.

(Continued on next page)
Background
The progressive aging of the population in industrialized countries is accompanied by a dramatic increase in the prevalence of multiple chronic diseases [1]. Traditionally, research has embraced the comorbidity conceptual framework, i.e. a framework which identifies an index disease and focuses on the probability of having other (secondary) diseases [2]. In an attempt to meet the complex problems posed by older patients with multiple chronic diseases, the attention has progressively shifted from the comorbidity to the multimorbidity conceptual framework. In this approach the co-occurrence of two or more diseases is taken into consideration without identifying an index disease [3, 4]. From the clinical point of view, the multimorbidity concept tends to push geriatric medicine towards an individual-oriented and no longer disease-oriented approach. Several different analytic approaches can be used to investigate multimorbidity. Studies explored multimorbidity by applying different methods (e.g. prevalence figures, conditional count, logistic regression models, cluster or network analysis and data mining techniques) to disease variables in different populations, and provided convincing evidence that chronic diseases may combine each other not simply due to chance [5–10].

Chronic kidney disease (CKD) is among the most frequent chronic conditions observed among older patients, and it dramatically impacts health status and survival in the general population, as well as in older populations [11–14]. Although CKD is known to be associated with several long lasting conditions, such as hypertension, diabetes, heart failure, anemia and osteoporosis, studies investigating patterns of multimorbidity including CKD provided heterogeneous results. Formiga et al. [6] showed that CKD may contribute to a multimorbidity cluster including cardio- and cerebro-vascular disease, atrial fibrillation, diabetes mellitus and visual impairment. More recently, CKD was found to contribute to a larger cluster including cardiovascular diseases (excluded coronary artery disease), endocrine abnormalities, neurological disorders including dementia, respiratory and muscle-skeletal diseases, infections and sensory impairment [10]. Thus, multimorbidity patterns involving CKD are worth of testing in other different populations.

Additionally, data about the impact of potentially relevant stratification variables on patterns of multimorbidity are very limited. Current evidence suggests that age, sex, and race/ethnicity may be associated with small but not negligible changes in multimorbidity patterns [10]. However, whether patterns of multimorbidity may change as a function of physical performance has not been investigated until now, despite the bidirectional interplay of multimorbidity and functional decline is more and more recognized as a crucial step in the assessment of health and care needs of older complex patients [15].

Finally, CKD severity may also affect multimorbidity patterns. Indeed, many of CKD-related concordant comorbidities, such as anemia, osteoporosis and heart failure, are known to be associated with the severity of CKD [16].

By including a detailed collection of data about diagnoses and comprehensive geriatric assessment including short physical performance battery (SPPB) [17], the Screening for CKD among Older People across Europe (SCOPE) study represents a valuable opportunity to explore multimorbidity patterns as well as the impact of physical performance and CKD severity on them in a
population of older community-dwelling people. These were the main objectives of our study.

**Methods**

The SCOPE study (European Grant Agreement no. 436849), is a multicenter 2-year prospective cohort study involving patients older than 75 years attending geriatric and nephrology outpatient services in participating institutions in Austria, Germany, Israel, Italy, the Netherlands, Poland and Spain. Methods of the SCOPE study have been extensively described elsewhere [18]. Briefly, all patients attending the outpatient services (7 geriatric and internal medicine and 2 nephrology services) at participating centers from August 2016 to August 2018 were asked to participate. Only patients signing a written informed consent entered the study. Age greater or equal to 75 years was the only inclusion criteria, the exclusion criteria were: end-stage renal disease or dialysis at time of enrollment; history of solid organ or bone marrow transplantation; active malignancy within 24 months prior to screening or metastatic cancer; life expectancy less than 6 months (based on the judgment of the study physician after careful medical history collection and diagnoses emerging from examination of clinical documentation exhibited); severe cognitive impairment (Mini Mental State Examination < 10); any medical or other reason (e.g. known or suspected patients’ inability to comply with the protocol procedure) in the judgement of the investigators, that the patient was unsuitable for the study; unwilling to provide consent and limited possibility to attend follow-up visits. The study protocol was approved by ethics committees at all participating institutions, and complies with the Declaration of Helsinki and Good Clinical Practice Guidelines. Only baseline data are used in the present study.

Overall, 2461 patients were initially enrolled in the study. Of them, 209 patients were excluded from this study because of incomplete baseline data, thus leaving a final sample of 2252 patients to be included in the analysis.

**Study variables**

Diagnoses were ascertained by the study physician by clinical history and physical examination. Physicians asked the participants to show all clinical records and prescription forms or drug containers of the drugs used. The following diagnoses were included in the analysis: hypertension, stroke, transient ischemic attack (TIA), cancer, hip fracture, osteoporosis, Parkinson’s disease, asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), angina, myocardial infarction, atrial fibrillation. Chronic kidney disease was defined on the basis of estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m². eGFR was calculated by creatinine-based Berlin Initiative Study (BIS) equation [19]. Such equation has been developed to be used in older people and has been externally validated against gold-standard measured GFR [20, 21]. Cognitive impairment was defined as age- and education-adjusted Mini Mental State Examination (MMSE) score less than 24 [22]. Depression was ascertained on the basis of Geriatric Depression Scale (GDS) score greater than 5 [23]. Vision and hearing impairment were coded on a scale from 0 (adequate) to 4 (no vision/hearing present) [24], and patients with at least mild deficit (scoring 1 or more) were considered as impaired. Anemia was defined as a hemoglobin level less than 13 g/dL in men and less than 12 g/dL in women. Multimorbidity was defined as the co-occurrence of two or more diseases.

Further variables included in the analysis were age, sex, and physical performance. Physical performance was measured by SPPB [17]. The SPPB includes gait speed (usual time to walk 4 m), five chair-stands test (time to rise from a chair and return to the seated position five times without using arms), and balance test (ability to stand with the feet together in the side-by-side, semi-tandem, and tandem positions). A score from 0 to 4 was assigned to performance on each task. Individuals received a score of 0 for each task they were unable to complete. Summing the three individual categorical scores, a summary performance score was created for each participant (range, 0–12), with higher scores indicating better lower body function. SPPB score was stratified using the following cut-offs: 9–12, best performance; 5–8, intermediate performance; 0–4, worst performance [17].

**Analytic approach**

First, descriptive analysis of the study population grouped according to SPPB score was provided. Data were reported as mean ± SD for continuous variables and number (percentage) for categorical ones. Chi-square test was used to analyze categorical variables, while ANOVA one way was used for continuous ones. For each chronic disease included in the analysis, its prevalence with and without co-occurring disease(s) was estimated. The expected prevalence of disease pairs involving CKD was computed and compared with the observed co-prevalence. To confirm the results of the pairs analysis and to control for possible confounders, logistic regression models were conducted to analyze the association between each pair of co-occurring diseases. This analysis was adjusted for age, sex, and all of the other diseases. To analyze different patterns of associative multimorbidity, without any a priori hypothesis, we used a hierarchical agglomerative clustering approach to create dendrograms. A binary distance measure (squared euclidean distance) was used to produce the
distance matrix resulting in more distinctive clusters compared with other proximity measures. For dendrograms analysis we used the Ward method as previously reported [10] to find compact clusters and minimizes the variance within clusters [25]. In order to investigate the impact of physical performance on multimorbidity patterns, analyses were repeated after stratification by SPPB score. Finally, in order to investigate the impact of CKD severity on patterns of multimorbidity, disease pairs and cluster analyses were repeated by using two additional eGFR thresholds, < 45 and < 30 ml/min/1.73 m², to define CKD.

Statistical analysis was carried out by using SPSS for Win V23.0 statistical software package (SPSS Inc., Chicago, IL, USA).

**Results**

**Descriptive analysis**

General characteristics of the study population are reported in Table 1. Age ranged between 75 and 96 years, and more than half of enrolled patients were women. CKD was among the most frequently observed conditions (66.0%), together with hypertension and sensory impairments (Table 1). CKD occurred without any other co-occurring disease in only 0.9% of participants. The corresponding figures for other diagnoses were 1.5% for hypertension, 1% for vision impairment, 0.4% for hearing impairment. All other diagnoses were also rarely present without any associated disease.

When stratifying population by physical performance, SPPB = 9–12 was observed in 1391 (61.8%) patients, while 614 patients (27.3%) had SPPB = 5–8, and 247 patients (11.0%) had SPPB = 0–4. This latter group included only a minority of patients (n = 24) not able to do any SPPB tasks and scoring 0 at physical performance assessment. Patients with lower SPPB scores were older and more frequently women (Table 1). Additionally, almost all diagnoses were more prevalent among physically impaired patients (Table 1).

**Patterns of multimorbidity and physical performance**

Observed and expected prevalence of the most frequently co-occurring pairs of diseases and their Table 1: General characteristics and prevalence of selected diseases among SCOPE study participants (N = 2252) and their distribution across physical performance status.

| Condition                  | All patients N = 2252 | SPPB score | P   |
|----------------------------|-----------------------|------------|-----|
|                            |                       | 9–12       | 5–8 | 0–4 |
| Age, years                 | 80.3 ± 4.1            | 79.6 ± 3.7 | 81.2 ± 4.4 | 82.4 ± 4.7 | < 0.001 |
| Sex, women                 | 1254 (55.7)           | 698 (50.2) | 381 (62.1) | 175 (70.9) | < 0.001 |
| Hypertension               | 1729 (76.8)           | 997 (71.7) | 509 (82.9) | 223 (90.3) | < 0.001 |
| CKD                        | 1487 (66.0)           | 871 (62.6) | 415 (67.6) | 201 (81.4) | < 0.001 |
| Vision impairment          | 1299 (57.7)           | 758 (54.5) | 370 (60.3) | 171 (69.2) | < 0.001 |
| Hearing impairment         | 1165 (51.7)           | 661 (47.5) | 348 (56.7) | 156 (63.2) | < 0.001 |
| Osteoporosis               | 687 (30.5)            | 324 (23.3) | 243 (39.6) | 120 (48.6) | < 0.001 |
| Diabetes                   | 566 (25.1)            | 280 (20.1) | 188 (30.6) | 98 (39.7)  | < 0.001 |
| Anemia                     | 476 (21.1)            | 228 (16.4) | 150 (24.4) | 98 (39.7)  | < 0.001 |
| Cancer                     | 388 (17.2)            | 234 (16.8) | 104 (16.9) | 50 (20.2)  | 0.413    |
| CHF                        | 373 (16.6)            | 187 (13.4) | 119 (19.4) | 67 (27.1)  | < 0.001 |
| Atrial fibrillation        | 344 (15.3)            | 159 (11.4) | 116 (18.9) | 69 (27.9)  | < 0.001 |
| Depression                 | 316 (14.0)            | 134 (9.6)  | 113 (18.4) | 69 (27.9)  | < 0.001 |
| COPD                       | 266 (11.8)            | 149 (10.7) | 86 (14)    | 31 (12.6)  | 0.101    |
| Myocardial infarction      | 217 (9.6)             | 112 (8.1)  | 65 (10.6)  | 40 (16.2)  | < 0.001 |
| TIA                        | 196 (8.7)             | 104 (7.5)  | 64 (10.4)  | 28 (11.3)  | 0.029    |
| Cognitive impairment       | 165 (7.3)             | 71 (5.1)   | 59 (9.6)   | 35 (14.2)  | < 0.001 |
| Angina                     | 133 (5.9)             | 72 (5.2)   | 39 (6.4)   | 22 (8.9)   | 0.062    |
| Stroke                     | 131 (5.8)             | 59 (4.2)   | 45 (7.3)   | 27 (10.9)  | < 0.001 |
| Asthma                     | 124 (5.5)             | 73 (5.2)   | 30 (4.9)   | 21 (8.5)   | 0.087    |
| Hip fracture               | 111 (4.9)             | 32 (2.3)   | 51 (8.3)   | 28 (11.3)  | < 0.001 |
| Parkinson                  | 45 (2.0)              | 11 (0.8)   | 17 (2.8)   | 17 (6.9)   | < 0.001 |

Data are mean ± SD or number of cases (percentage)
association are shown in Table 2. The most frequent co-occurring pairs involving CKD were those with hypertension, sensory impairments, osteoporosis, diabetes and anemia. After adjusting for age, sex and all other diseases included in the analyses, CKD was significantly associated with hypertension, anemia, CHF, atrial fibrillation, myocardial infarction and hip fracture, while near significant associations were observed with hearing impairment, diabetes and cancer (Table 2). It is worth noting that 89.4% of diabetic patients were also affected by hypertension, and the association between CKD and diabetes became significant when removing hypertension from the fully adjusted model (OR = 1.36, 95%CI = 1.08–1.71).

When stratifying pairs analysis by physical performance, CKD was significantly associated with hypertension (OR = 1.66, 95%CI = 1.28–2.14), CHF (OR = 1.63, 95%CI = 1.09–2.43), atrial fibrillation (OR = 1.82, 95%CI = 1.18–2.79) and hip fracture (OR = 0.34, 95%CI = 0.15–0.76) among patients with SPPB score = 9–12. At variance, the significant co-occurring pairs involving CKD were those with hypertension (OR = 2.79, 95%CI = 1.22–4.52), CHF (OR = 2.39, 95%CI = 1.27–4.47), anemia (OR = 3.68, 95%CI = 2.09–6.48) and vision impairment (OR = 1.50, 95%CI = 1.02–2.20) among patients with SPPB = 5–8. Finally, significant co-occurring pairs among patients with SPPB = 0–4 were those involving hypertension (OR = 3.54, 95%CI = 1.21–10.4), anemia (OR = 2.10, 95%CI = 1.03–4.68) and hearing impairment (OR = 2.20, 95%CI = 1.02–4.93).

Finally, patterns of multimorbidity from cluster analysis are reported in Fig. 1. Overall, cluster analysis individuated two main clusters, one including CKD, hypertension and sensory impairments, and the second including all other conditions. When stratifying this analysis by SPPB, these patterns were substantially confirmed among patients with SPPB = 9–12 or SPPB = 5–8. At variance, the pattern of multimorbidity involving CKD was clearly different among patients with lowest level of physical performance where a sub-cluster including diabetes, anemia and osteoporosis appeared near to the one including hypertension, CKD and sensory impairments. When repeating this latter analysis after excluding 24 patients scoring 0 at SPPB assessment, the dendrogram remained unchanged (not shown).

### Patterns of multimorbidity and CKD severity

When defining CKD as eGFR< 45 or 30 ml/min/1.73 m², the strength of the association of CKD with hypertension, sensory impairments, osteoporosis, anemia and CHF increased together with CKD severity (Table 3). Finally, patterns of multimorbidity also changed significantly in relation to CKD severity. Indeed, eGFR< 45 ml/min/1.73 m² contributed to a sub-cluster including anemia, diabetes and osteoporosis, while severe CKD

---

**Table 2** Observed and expected prevalence of co-occurring pairs of diseases involving CKD in the whole study population (N = 2252)

| Co-occurring pairs | Cases | Observed | Expected | Obs/Exp ratio | Adjusted for age and sex | Fully adjusted |
|--------------------|-------|----------|----------|---------------|--------------------------|---------------|
| CKD Hypertension   | 1224  | 54.4     | 50.7     | 1.07          | 2.30                     | 1.87–2.82     |
| CKD Vision impairment | 880   | 39.1     | 38.1     | 1.03          | 1.25                     | 1.04–1.50     |
| CKD Hearing impairment | 822   | 36.5     | 34.2     | 1.07          | 1.37                     | 1.15–1.64     |
| CKD Osteoporosis   | 449   | 19.9     | 20.1     | 0.99          | 1.02                     | 0.83–1.25     |
| CKD Diabetes       | 420   | 18.7     | 16.6     | 1.12          | 1.63                     | 1.31–2.03     |
| Anemia CKD         | 388   | 17.2     | 13.9     | 1.24          | 2.26                     | 1.75–2.92     |
| CHF CKD            | 305   | 13.5     | 10.9     | 1.24          | 2.47                     | 1.86–3.29     |
| Cancer CKD         | 282   | 12.5     | 11.4     | 1.10          | 1.36                     | 1.06–1.75     |
| Atrial fibrillation CKD | 276   | 12.3     | 10.1     | 1.22          | 2.07                     | 1.55–2.75     |
| CKD Depression     | 212   | 9.4      | 9.3      | 1.02          | 1.06                     | 0.81–1.37     |
| CKD COPD           | 202   | 9.0      | 7.8      | 1.15          | 1.58                     | 1.16–2.14     |
| CKD Myocardial infarction | 182   | 8.1      | 6.4      | 1.27          | 2.46                     | 1.68–3.61     |
| CKD TIA            | 136   | 6.0      | 5.7      | 1.05          | 1.07                     | 0.77–1.49     |
| CKD Cognitive impairment | 120   | 5.3      | 4.8      | 1.10          | 1.15                     | 0.80–1.67     |
| CKD Stroke         | 98    | 4.4      | 3.8      | 1.13          | 1.37                     | 0.90–2.07     |
| Angina CKD         | 94    | 4.2      | 3.9      | 1.07          | 1.17                     | 0.79–1.74     |
| Asthma CKD         | 81    | 3.6      | 3.6      | 0.99          | 1.03                     | 0.69–1.52     |
| CKD Hip fracture   | 65    | 2.9      | 3.3      | 0.89          | 0.57                     | 0.38–0.86     |
| CKD Parkinson      | 31    | 1.4      | 1.3      | 1.04          | 0.94                     | 0.49–1.82     |
defined as eGFR < 30 ml/min/1.73 m² contributed to a wide cluster including cardiovascular, respiratory and neurologic diseases, as well as osteoporosis, hip fracture and cancer Fig. 2.

Discussion
Findings from the present study suggests that CKD significantly contributes to multimorbidity patterns in a population of older outpatients. Additionally, simple count of disease may hide several important information otherwise obtained by the analysis of most relevant pairs of co-occurring disease or disease clusters. Indeed, as already reported in former studies [5, 6, 26, 27] the occurrence of individual conditions without any associated disease was rarely observed in our study population. Finally, and in a relevant way, our study also suggests that multimorbidity patterns may change as a function of physical performance as assessed by SPPB.

The most relevant co-occurring pairs involving CKD observed in our study where those with hypertension, anemia, CHF, atrial fibrillation, myocardial infarction, hip fracture, and to a lesser extent hearing impairment, diabetes and cancer. The weak association between CKD and diabetes was not surprising given that almost all diabetic patients also had high blood pressure in our study and removing hypertension from the multivariable model made statistically significant such association in pairs analysis. Additionally, it is worth noting that after
| Co-occurring pairs | Cases | Observed % | Expected % | Obs/Exp ratio | Adjusted for age and sex | Fully adjusted |
|--------------------|-------|------------|------------|---------------|--------------------------|---------------|
|                    |       |            |            |               | OR 95%CI                  | OR 95%CI       |
| **CKD = eGFR < 45 ml/min/1.73 m²** |       |            |            |               |                          |               |
| CKD Hypertension   | 509   | 22.6       | 19.0       | 1.2           | 3.87                     | 2.82–5.30     | 3.01          | 2.14–4.20    |
| CKD Vision impairment | 359  | 15.9       | 14.3       | 1.1           | 1.56                     | 1.26–1.91     | 1.21          | 0.95–1.53    |
| CKD Hearing impairment | 360 | 16.0       | 12.8       | 1.2           | 1.79                     | 1.46–2.19     | 1.48          | 1.17–1.87    |
| CKD Osteoporosis   | 186   | 8.3        | 7.6        | 1.1           | 1.38                     | 1.10–1.73     | 1.22          | 0.94–1.56    |
| CKD Diabetes       | 211   | 9.4        | 6.2        | 1.5           | 2.31                     | 1.86–2.86     | 1.62          | 1.27–2.04    |
| Anemia CKD         | 245   | 10.9       | 5.2        | 2.1           | 4.21                     | 3.36–5.26     | 3.64          | 2.86–4.61    |
| CHF CKD            | 149   | 6.6        | 4.1        | 1.6           | 2.21                     | 1.73–2.81     | 1.34          | 1.00–1.79    |
| Cancer CKD         | 121   | 5.4        | 4.3        | 1.3           | 1.36                     | 1.06–1.74     | 1.21          | 0.92–1.58    |
| Atrial fibrillation | 124  | 5.5        | 3.8        | 1.5           | 1.64                     | 1.27–2.11     | 1.19          | 0.88–1.59    |
| CKD Depression     | 78    | 3.5        | 3.5        | 1.0           | 0.99                     | 0.74–1.32     | 0.79          | 0.57–1.08    |
| CKD COPD           | 95    | 4.2        | 2.9        | 1.4           | 1.65                     | 1.24–2.18     | 1.31          | 0.95–1.80    |
| CKD Myocardial infarction | 107  | 4.8        | 2.4        | 2.0           | 2.89                     | 2.14–3.89     | 2.00          | 1.43–2.78    |
| CKD TIA            | 58    | 2.6        | 2.2        | 1.2           | 1.15                     | 0.82–1.61     | 0.95          | 0.65–1.39    |
| CKD Cognitive impairment | 46  | 2.0        | 1.8        | 1.1           | 0.98                     | 0.67–1.41     | 0.90          | 0.60–1.35    |
| CKD Stroke         | 46    | 2.0        | 1.4        | 1.4           | 1.49                     | 1.01–2.18     | 1.21          | 0.78–1.85    |
| Angina CKD         | 49    | 2.2        | 1.5        | 1.5           | 1.74                     | 1.19–2.55     | 0.98          | 0.62–1.52    |
| Asthma CKD         | 32    | 1.4        | 1.4        | 1.0           | 1.15                     | 0.74–1.76     | 0.93          | 0.58–1.49    |
| CKD Hip fracture   | 24    | 1.1        | 1.2        | 0.9           | 0.66                     | 0.40–1.06     | 0.67          | 0.39–1.15    |
| CKD Parkinson      | 14    | 0.6        | 0.5        | 1.2           | 1.15                     | 0.59–2.22     | 0.80          | 0.38–1.66    |
| **CKD = eGFR < 30 ml/min/1.73 m²** |       |            |            |               |                          |               |
| CKD Hypertension   | 135   | 6.0        | 4.8        | 1.3           | 8.44                     | 3.43–20.7     | 5.73          | 2.29–14.3    |
| CKD Vision impairment | 107  | 4.8        | 3.6        | 1.3           | 2.71                     | 1.81–4.06     | 1.79          | 1.13–2.81    |
| CKD Hearing impairment | 103 | 4.6        | 3.2        | 1.4           | 2.49                     | 1.68–3.66     | 1.69          | 1.09–2.61    |
| CKD Osteoporosis   | 64    | 2.8        | 1.9        | 1.5           | 2.79                     | 1.90–4.08     | 2.22          | 1.46–3.34    |
| CKD Diabetes       | 51    | 2.3        | 1.6        | 1.5           | 1.69                     | 1.17–2.42     | 1.16          | 0.77–1.71    |
| Anemia CKD         | 83    | 3.7        | 1.3        | 2.8           | 5.53                     | 3.83–7.96     | 4.64          | 3.16–6.79    |
| CHF CKD            | 49    | 2.2        | 1.0        | 2.1           | 2.70                     | 1.86–3.91     | 1.77          | 1.14–2.73    |
| Cancer CKD         | 34    | 1.5        | 1.1        | 1.4           | 1.45                     | 0.96–2.17     | 1.26          | 0.81–1.93    |
| Atrial fibrillation | 32    | 1.4        | 0.9        | 1.5           | 1.46                     | 0.95–2.22     | 0.96          | 0.59–1.55    |
| CKD Depression     | 19    | 0.8        | 0.9        | 0.9           | 1.00                     | 0.60–1.65     | 0.81          | 0.46–1.38    |
| CKD COPD           | 25    | 1.1        | 0.7        | 1.5           | 1.45                     | 0.91–2.30     | 0.97          | 0.56–1.65    |
| CKD Myocardial infarction | 28  | 1.2        | 0.6        | 2.0           | 2.05                     | 1.30–3.21     | 1.49          | 0.89–2.50    |
| CKD TIA            | 11    | 0.5        | 0.5        | 0.9           | 0.78                     | 0.40–1.47     | 0.64          | 0.31–1.28    |
| CKD Cognitive impairment | 7   | 0.3        | 0.5        | 0.7           | 0.57                     | 0.25–1.25     | 0.54          | 0.23–1.23    |
| CKD Stroke         | 13    | 0.6        | 0.4        | 1.7           | 1.52                     | 0.82–2.78     | 1.35          | 0.68–2.65    |
| Angina CKD         | 8     | 0.4        | 0.4        | 1.1           | 0.88                     | 0.41–1.84     | 0.46          | 0.20–1.03    |
| Asthma CKD         | 7     | 0.3        | 0.3        | 0.9           | 0.99                     | 0.44–2.16     | 0.87          | 0.38–1.99    |
| CKD Hip fracture   | 7     | 0.3        | 0.3        | 1.0           | 0.93                     | 0.41–2.07     | 0.83          | 0.34–1.98    |
| CKD Parkinson      | 4     | 0.2        | 0.1        | 1.6           | 1.27                     | 0.44–3.63     | 0.85          | 0.27–2.63    |
stratification by SPPB score other significant pairs emerged among patients with SPPB = 5–8 (vision impairment) and SPPB = 0–4 (hearing impairment). Thus, it seems that a simple physical performance test, already known to predict mobility disability, ADL dependency, rehospitalization and death [28–31], may also help to describe patients with somewhat different profiles of co-occurring pairs of diseases.

While the association between CKD and cardiovascular diseases, anemia, diabetes and mineral bone disease (including fractures) is well recognized and extensively addressed in clinical guidelines where specific recommendations are provided for these conditions [32], the combination of CKD with cancer and sensory impairments deserves to be discussed. Chronic kidney disease (CKD) and cancer are strictly related to each other. Cancer can cause CKD either directly or indirectly through the adverse effects of treatments. Conversely, CKD may represent a relevant risk factor for cancer [33]. Indeed, though the increased risk of death observed among CKD patients is mainly attributable to cardiovascular disease, the incidence of cancer is also increased [16]. Cancer can affect the kidney either as glomerular lesions or as a result of the toxic effects of medication or radiation with acute (thrombotic microangiopathy, acute kidney injury, interstitial nephropathies among others) or chronic processes (worsening of CKD after nephrectomy due to renal cancer, interstitial fibrosis, water and electrolytes disorders) [34]. It is worth noting that we only considered history of cancer in our study, while patients carrying active malignancies during the last 24 months before enrollment were excluded. Nevertheless, older cancer survivors may be more likely to develop frailty or worsening of the health status, and such association may be especially relevant among individuals with a recent (< 10 years) history of cancer [35].

Given the mean age of enrolled patients, the association between CKD and sensory impairment may be simply related to older age independent of kidney function. However, several potential mechanisms may underly such association. Hearing loss was found to be highly prevalent among CKD patients [36, 37], and increasing serum creatinine or blood pressure was found associated with increasing hearing threshold [38]. Several similarities between cochlea and kidney can be observed, including membranous structures, the central role of ciliated epithelial cells, and tubular organization [39]. In experimental uremic animals, a significant decrease in cochlear Na⁺-K⁺-ATPase activity resulted in hearing impairment [40]. Additionally, ototoxic medications may also contribute to the observed association. For example, furosemide may affect ionic gradients between the endolymph and perilymph thus altering endocochlear potential and leading to cochlear dysfunction [41]. The association between CKD and vision impairment was also reported to be highly prevalent in CKD patients [36]. A population study involving 10,033 adults aged 40–80 years showed that the prevalence of vision impairment and ocular disease were significantly higher in participants with (36.1 and 84.7%) compared to those without CKD (12.9 and 54.3%, both p < 0.001) [42]. Diabetic retinopathy and age-related macular degeneration are most consistently associated with CKD [43]. It is worth noting that mechanisms underlying CKD, such as vascular remodeling, endothelial dysfunction, atherosclerosis, inflammation, and oxidative stress are also involved in the development of many eye diseases. Besides diabetes and hypertension, metabolic disorders associated with CKD,
such as oxidative stress, uremia, anemia, as well as specific treatment, such as steroids and dialysis may be also involved [43]. Despite this bulk of evidence, screening for vision and hearing impairment is not currently recommended in CKD clinical guidelines and our findings suggest for its potential usefulness in this vulnerable population.

Cluster analysis provided quite consistent results showing that CKD may contribute to a cluster of multimorbidity including hypertension and sensory impairments in the whole study population. These findings are somewhat different from those reported in former studies and characteristics of population, as well as the list of diagnoses included in the analysis likely account for these differences. Marengoni et al. identified five major clusters (two linked to vascular diseases with hypertension and heart failure playing the main role and the others to dementia, diabetes mellitus, and malignancy) in a population of 1099 community-dwelling people aged 77 or more. However, CKD was not included in the list of diagnoses [5]. In the study by Formiga et al. [6], the list of diagnoses was very similar to that in our study and four main clusters were identified in a population of 328 oldest old people aged 85 or more. CKD contributed to a multimorbidity cluster including atrial fibrillation, heart failure, visual impairment, stroke, hypertension and diabetes mellitus [6]. More recently, Zemedikun et al. [10] identified 3 main multimorbidity clusters with CKD contributing to the wide cluster including cardiovascular diseases (excluded coronary artery disease), endocrine abnormalities, neurological disorders including dementia, respiratory and muscle-skeletal diseases, infections and sensory impairment. However, at variance from our study their analysis was carried out in a population younger than 70 years [10].

Interestingly, when stratifying analysis according to physical performance, the cluster including CKD was “enriched” by a sub-cluster including anemia and osteoporosis (i.e. two well-known complications of CKD, namely CKD-related anemia and CKD-Mineral Bone Disease (CKD-MBD)) and diabetes (i.e. a leading cause of CKD) among patients with lowest SPPB scores. Thus, both co-occurring pairs and clustering of diseases may change as a function of SPPB among older people in the present study, and SPPB is among the most useful frailty tools for the identification of patients that may benefit from interventions aimed at improving functional capacity in primary care settings [44]. Our findings are in keeping with current guidelines stating that frailty and sensory impairments are very relevant items when investigating multimorbidity, while defining multimorbidity by simple counts of health conditions may be misleading [45]. Indeed, current evidence suggests that frailty and multimorbidity are strictly related each other in older adults [46, 47]. Additionally, physical performance assessed by gait speed and grip strength was recently found significantly associated with both the development of multimorbidity and worsening pre-existing multimorbidity, with evidence of a dose–response relationship [48]. Our results further strengthen the need to assess physical function in clinical practice and to establish specific function-oriented interventions able to reduce the burden of multimorbidity and related negative outcomes.

Finally, this is the first study including CKD severity in the analysis of multimorbidity patterns. Indeed, CKD severity was not considered in former multimorbidity studies [6, 10]. Besides confirming that the strength of the association between CKD and selected complications, i.e. hypertension, sensory impairments, osteoporosis, anemia and CHF may increase together with CKD severity [16], our study adds to current knowledge by showing that the complexity of multimorbidity cluster including CKD may also change in relation to CKD severity. These findings suggest that severity of individual diseases should be taken into consideration in future studies of multimorbidity among older complex patients.

Limitations of our study deserve to be mentioned. The cross-sectional design did not allow to investigate pathways leading to multimorbidity and the prognostic impact of specific multimorbidity patterns. Additionally, the list of diagnoses included in the analysis could not be considered exhaustive. However, we used a list of diagnoses very similar to that already used in studies investigating multimorbidity patterns. Nevertheless, the prevalence of individual diseases and that of individual diagnoses with multimorbidity was somewhat higher in the SCOPE study population compared to former studies [5, 6, 10], likely because we enrolled older people attending outpatients services in participating institutions with an extensive assessment and a complete analysis of clinical documentation exhibited by patients and caregivers, while former studies were population-based [5, 6, 10]. Our study did not include the assessment of severity of each individual disease other than CKD and findings from CKD severity analysis suggest that disease severity may represent a relevant confounder. The very rare occurrence of selected diagnoses without multimorbidity prevented us to explore differences between patients with and without multimorbidity. Finally, we need to recognize that while the analysis of co-occurring pairs may have an immediate clinical relevance, results obtained by hierarchical cluster analysis of diagnoses is less easy to be translated to clinical practice. Nevertheless, these exploratory data may represent a sound scientific basis for future studies on the clinical characterization of patient clusters and/or groups carrying specific multimorbidity patterns involving CKD. This study also has
important strengths, including the enrollment of a real-world European population of older community-dwelling people and the opportunity to investigate the impact of objectively measured physical performance on patterns of multimorbidity.

Conclusions
CKD contributes significantly to multimorbidity in a population of older outpatients and it was rarely observed without any co-occurring disease. The most significant co-occurring pairs involving CKD included hypertension, anemia, CHF, atrial fibrillation, myocardial infarction, hip fracture, and to a lesser extent hearing impairment, diabetes and cancer. Cluster analysis showed that CKD may cluster with hypertension and sensory impairments. Physical performance as assessed by SPPB may be associated with not negligible changes in both co-occurring pairs and multimorbidity clusters. These findings strengthen the need of assessing physical performance and investigating interventions targeting physical function among complex multimorbid patients in an attempt to improve outcomes and reduce costs associated with multimorbidity. Finally, CKD severity may significantly affect patterns of multimorbidity, which suggests that disease severity should be further investigated in multimorbidity studies.

Abbreviations
ADL: Activities of Daily living; BIS: Berlin Initiative Study; CHF: Congestive heart failure; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; eGFR: Estimated glomerular filtration rate; SPPB: Short physical performance battery; TIA: Transient ischemic attack

Acknowledgements
SCOPE study investigators
Coordinating center, Fabrizia Lattanzio, Italian National Research Center on Aging (INRCA), Ancona, Italy – Principal Investigator. Andrea Corsonello, Silvia Bustacchini, Silvia Bolognini, Paola D’Ascoli, Raffaella Morei, Giuseppina Di Stefano, Cinzia Gaimarri, Anna Rita Bonfigli, Roberta Galeazzi, Federico Lenci, Stefano Della Bella, Enrico Bordoni, Mauro Provinciali, Robertina Gacionni, Cinzia Giuli, Demetrio Pastacchini, Sabrina Garasto, Annalisa Cozza, Francesco Guarasci, Sonia D’Alia - Italian National Research Center on Aging (INRCA), Ancona, Fermo and Cosenza, Italy – Coordinating staff. Romano Firmani, Moreno Nacciariti, Mirko Di Rosa, Paolo Fabbietti – Technical and statistical support.

Participating centers
• Department of Internal Medicine, Medical University of Graz, Austria: Gerhard Hubert Wünsbner, Regina Elisabeth Roller-Wünsbner, Carolin Herzog, Sonja Lindner
• Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands: Francesco Mattace-Raso, Lisanne Tap, Gijbertus Ziere, Jeannette Goudswaard.
• Department of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Poland; Tomasz Kostka, Agnieszka Guliowska, Lukasz Kroc, Bartłomiej K Sobtyś, Małgorzata Piglowska, Agnieszka Wójcik, Zuzanna Chrząstek, Natalia Sosowska, Anna Telęska, Joanna Kostka, Elżbieta Fife, Katarzyna Smij, Kinga Zel.
• The Recanati School for Community Health Professions at the faculty of Health Sciences at Ben-Gurion University of the Negev, Israel: Rada Arzti-Medvedik, Yehudit Melzer, Mark Clarfield, Isthak Melzer; and Maccabi Healthcare services southern region, Israel: Rada Arzti-Medvedik, Ilan Yehoshua, Yehudit Melzer.
• Geriatric Unit, Internal Medicine Department and Nephrology Department, University Hospital of Bellvitge, Institut d’Investigació Biomédica de Bellvitge - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain: Francesc Formiga, Rafael Moreno-González, Xavier Corbella, Yurema Martinez, Carolina Polo, Josep Maria Cruzados.
• Department of Geriatric Medicine, Hospital Clinico San Carlos, Madrid: Pedro Gil Gregorio, Sara Lainéz Martínez, Mónica González Alonso, Jose A. Herrero Calvo, Fernando Toméro Molina, Lara Guardado Fuentes, Pamela Carrillo García, María Mombiedro Pérez.
• Department of General Internal Medicine and Geriatrics, Krankenhaus Barnmutter中国队 Regensburg and Institute for Biomedicine of Aging, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany: Alexandra Renz, Susanne Muck, Stephan Theobaldy, Andreas Bekmann, Revelda Kalta, Sabine Britting, Robert Kob, Christian Weingart, Ellen Freiberger, Cornel Sieber.
• Department of Medical Sciences, Uppsala University, Sweden: Johan Arnlov, Axel Carlsson, Tobias Feldreich.

Scientific advisory board (SAB)
Roberto Bernabei, Catholic University of Sacred Heart, Rome, Italy
Christophe Bula, University of Lausanne, Switzerland
Hermann Haller, Hannover Medical School, Hannover, Germany
Carmine Zoccali, CNR-IBIM Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy

Data and Ethics Management Board (DEMB)
Dr. Kitty Jager, University of Amsterdam, The Netherlands
Dr. Wim Van Biesen, University Hospital of Ghent, Belgium
Paul E. Stevens, East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom
We thank the BioGer IRCCS INRCA Biobank for the collection of the SCOPE samples.

About this supplement
This article has been published as part of BMC Geriatrics Volume 20 Supplement 1 2020: The Screening for Chronic Kidney Disease among Older People across Europe (SCOPE) project: findings from cross-sectional analysis. The full contents of the supplement are available at https://bmcgeriatr.biomedcentral.com/articles/supplements/volume-20-supplement-1.

Authors’ contributions
AC and FL conceived the study, coordinated study protocol and data collection, participated in manuscript drafting and revising. PF participated in study protocol design, data analysis, writing of the manuscript and taking responsibility for the publication process. RW, GW, TK, AG, FMR, LT, PG, SL, IM, FF, RMG, CW, IY, EF, JÀ, ACC participated in study protocol design, data collection, and manuscript revision and approval. The author(s) read and approved the final manuscript.

Funding
SCOPE study and publication costs are funded by the European Union Horizon 2020 program, under the Grant Agreement no 634869. Funding body had no role in the design of the study and collection, analysis, and interpretation of data, writing the manuscript and in the decision to publish the results.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the SCOPE repository (www.scopeproject.eu).

Ethics approval and consent to participate
The study protocol was approved by ethics committees at all participating institutions, and complies with the Declaration of Helsinki and Good Clinical Practice Guidelines. All patients signed a written informed consent to be enrolled. Only baseline data are used in the present study. Ethics approvals have been obtained by Ethics Committees in participating institutions as follows:
• Italian National Research Center on Aging (INRCA), Italy, #2015 0522 IN, January 27, 2016.
• University of Lodz, Poland, #RNN/314/15/KE, November 17, 2015.
• Medizinische Universität Graz, Austria, #28–314 ex 15/16, August 5, 2016
• Erasmus Medical Center Rotterdam, The Netherlands, #MEC-2016-036 - #NL56039.078.15, v.4, March 7, 2016.
Hospital Clínico San Carlos, Madrid, Spain, # 15/532-E-BC, September 16, 2016
Bellvitge University Hospital Barceloneta, Spain, #PR204/15, January 29, 2016.
Friedrich-Alexander University Erlangen-Nürnberg, Germany, #340_158, January 21, 2016.
Helsinki committee in Maccabi Healthcare services, Bat Ba-lev, Bat Yam, Israel, #45/2016, July 24, 2016.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Italian National Research Center on Aging (IRCCS INRCA), Ancona, Fermo and Cosenza, Italy. 2Laboratory of Geriatric Pharmacopeidemiology and Biostatistics, IRCCS INRCA, Via S. Margherita 60, 60124 Ancona, Italy. 3Geriatric Unit, Internal Medicine Department, Bellvitge University Hospital – IDIBELL – L’Hospitalet de Llobregat, Barcelona, Spain. 4Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 5Department of Internal Medicine, Medical University of Graz, Graz, Austria. 6Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 7School of Health and Social Studies, Dalarna University, Falun, Sweden. 8Division of Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden. 9Department of General Internal Medicine and Geriatrics, Institute for Biomedicine of Aging, Krankenhaus Barmherzige Brüder, Friedrich-Alexander-Universität Erlangen-Nürnberg, Regensburg 93049, Germany. 10Department of Internal Medicine-Geriatrics, Institute for Biomedicine of Aging, Krankenhaus Barmherzige Brüder, Friedrich-Alexander-Universität Erlangen-Nürnberg, Kögberger Strasse 60, 90408 Nuremberg, Germany. 11Department of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Lodz, Poland. 12Department of Geriatric Medicine, Hospital Clínico San Carlos, Madrid, Spain. 13The Recanati School for Community Health Professions at the faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel. 14Maccabi Health Organization, Negev District, Israel.

Received: 6 August 2020 Accepted: 11 August 2020
Published: 2 October 2020

References
1. Banerjee S. Multimorbidity—older adults need health care that can count past one. Lancet. 2015;385(9968):587–9.
2. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–68.
3. Mercer SW, Smith SM, Wyke S, O'Dowd T, Watt GC. Multimorbidity in general practice: developing the research agenda. Fam Pract. 2009;26(2):79–80.
4. Starfield B, Kinder K. Multimorbidity and its measurement. Health Policy. 2011;103(1):3–8.
5. Marengoni A, Rizzato D, Wang HX, Winblad B, Fratiglioni L. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57(2):225–30.
6. Formiga F, Ferrer A, Sanz H, Marengoni A, Alburquerque J, Pujol R. Octabax Study. M. Patterns of comorbidity and multimorbidity in the oldest old: the Octabax study. Eur J Intern Med. 2013;24(1):40–44.
7. Fougert-Boreu Q, Violan C, Rodriguez-Blanco T, Roso-Llorach A, Pons-Vígues M, Pujol-Ribera E, Cosio Gil Y, Valderas JM. Multimorbidity patterns in elderly primary health care patients in a South Mediterranean European region: a cluster analysis. PLoS One. 2013;10(1):e141155.
8. Heid FP, Blyth F, Gnjidic D, Hirani V, Naganathan V, Waite LM, Seibel MJ, Rollo J, Handelsman DJ, Cumming RG, et al. Association rules analysis of comorbidity and multimorbidity: the concord health and aging in men project. J Gerontol A Biol Sci Med Sci. 2016;71(5):625–31.
9. Collerton J, Jagger C, Yadenofar ME, Davies K, Parker SG, Robinson L, Kirkwood TB. Deconstructing complex multimorbidity in the very old: findings from the Newcastle 85+ study. Biomed Res Int. 2016;2016:7847670.
10. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK biobank data. Mayo Clin Proc. 2018;93(7):857–66.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
12. Anavekar NS, McMurtry JJ, Velazquez EJ, Solomon MD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.
13. Corsonello A, Pedone C, Lattanzio F, Cherubini A, Onorati M, Delafontaine P, Grisotti L. Multimorbidity and functional impairment: bidirectional interplay, synergistic effects and common pathways. J Intern Med. 2018;283(3):255–71.
14. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
15. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.
16. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
17. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.
18. Corsonello A, Tap L, Rollin-Wirnsberger R, Wirnsberger G, Zoccali C, Kostka T, Guligowska A, Mattace-Raso F, Gil P, Fuentes LG, et al. Design and methodology of the screening for CKD among older patients across Europe (SCPOE) study: a multicenter cohort observational study. BMC Nephrol. 2018;19(1):260.
19. Scheffner ES, Ebert N, Delaney P, Frei U, Gerdthämer J, Schiefelbein A, Neumann T, Ziegler M, Ziegler S, et al. Number of clinical events to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157(7):471–81.
20. Althauer IM, Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, Farmer CK, Irving J, O'Riordan SE, et al. External validation of the Berlin equations for estimation of GFR in the elderly. Am J Kidney Dis. 2014;63(5):862–5.
21. da Silva Sellistre L, Rech DL, de Souza V, Iwaz J, Lemoine S, Dubourg L. Diagnostic performance of creatinine-based equations for estimating glomerular filtration rate in adults 65 years and older. JAMA Intern Med. 2019;179(6):796–804.
22. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
23. Lesher EL, Berryhill JS. Validation of the geriatric depression scale--short form. Arch Gen Psychiatry. 1982;39(6):681–4.
24. Jelliffe EP. Body mass index and its uses. J Chronic Dis. 1970;23(7):455–68.
25. Becker RA, Chambers JM, Wils AR. The new S language. Pacific Grove: Wadsworth & Brooks; 1988.
26. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. The new S language. Pacific Grove: Wadsworth & Brooks; 1988.
27. Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
28. Anavekar NS, McMurtry JJ, Velazquez EJ, Solomon MD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.
29. Corsonello A, Pedone C, Lattanzio F, Cherubini A, Onorati M, Delafontaine P, Grisotti L. Multimorbidity and functional impairment: bidirectional interplay, synergistic effects and common pathways. J Intern Med. 2018;283(3):255–71.
30. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
31. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.
loss of ability to walk 400 meters: analysis from the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2009;64(2):223–9.

31. Volpato S, Cavalieri M, Soulios F, Guerra G, Maraldi C, Zuliani G, Fellin R, Guralnik JM. Predictive value of the short physical performance battery following hospitalization in older patients. J Gerontol A Biol Sci Med Sci. 2011;66(1):89–96.

32. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;2013(3):1–150.

33. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23(3):253–62.

34. de Francisco ALM, Macia M, Alonso F, Garcia P, Gutierrez E, Quintana LF, Quiroga B, Torregrosa I. Onco nephrology. cancer, chemotherapy and kidney. Nefrologia. 2019;39(5):473–81.

35. Perez-Zepeda MU, Cardenas-Cardenas E, Cesari M, Navarrete-Reyes AP, Gutierrez-Rubledo LM. Cancer and frailty in older adults: a nested case-control study of the Mexican health and aging study. J Cancer Surviv. 2016;10(4):736–42.

36. Jamaldeen J, Basheer A, Sarma AC, Kandasamy R. Prevalence and patterns of hearing loss among chronic kidney disease patients undergoing haemodialysis. Australas Med J. 2015;8(2):41–6.

37. Antonelli AR, Bonfili F, Garubba V, Ghisellini M, Lamoretti MP, Nicolai P, Camerini C, Maiorca R. Audiological findings in elderly patients with chronic renal failure. Acta Otolaryngol Suppl. 1990;190:54–68.

38. Seo YJ, Koh SB, Ha TH, Gong TH, Bong JP, Park DJ, Park SY. Association of hearing impairment with chronic kidney disease: a cross-sectional study of the Korean general population. BMC Nephrol. 2015;16:154.

39. Thodi C, Thodis E, Danielides V, Papadakis P, Vargemezis V. Hearing in renal failure. Nephrol Dial Transplant. 2006;21(11):3023–30.

40. Adler D, Finet W, Ritz E. Inhibition of Na+,K+-stimulated ATPase in the cochlea of the guinea pig. A potential cause of disturbed inner ear function in terminal renal failure. Acta Otolaryngol Suppl. 1990;476:55–60.

41. Schmiedt RA, Lang H, Okamura HO, Schulte BA. Effects of furosemide applied chronically to the round window: a model of metabolic presbyacusis. J Neurosci. 2002;22(21):9643–50.

42. Wong CW, Lamoureux EL, Cheng CY, Cheung GC, Tai ES, Wong TY. Sabanayagam C. Increased burden of vision impairment and eye diseases in persons with chronic kidney disease - a population-based study. EBioMedicine. 2016;5:193–7.

43. Nusinovici S, Sabanayagam C, Teo BW, Tan GSW, Wong TY. Vision impairment in CKD patients: epidemiology, mechanisms, differential diagnoses, and prevention. Am J Kidney Dis. 2019;73(6):846–57.

44. Vergara I, Mateo-Abad M, Saucedo-Figueroedo MC, Machon M, Montiel-Luque A, Vrotsou K, Nava Del Val MA, Diez-Ruiz A, Guell C, Mathieu A, et al. Description of frail older people profiles according to four screening tools applied in primary care: a cross sectional analysis. BMC Geriatr. 2019;19(1):342.

45. Farmer C, Fenu E, Offley N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843.

46. Vetranio DL, Calderon-Laranaga A, Marengoni A, Onder G, Bauer JM, Cesari M, Ferrucci L, Fratiglioni L. An international perspective on chronic multimorbidity: approaching the elephant in the room. J Gerontol A Biol Sci Med Sci. 2018;73(10):1350–6.

47. Vetranio DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wimmberger R, Lopez Samaniego I, Rodriguez-Manas L, Bernabei R, Onder G, et al. Frailty and multimorbidity: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2019;74(5):659–66.

48. Ryan A, Murphy C, Boland F, Galvin R, Smith SM. What is the impact of physical activity and physical function on the development of multimorbidity in older adults over time? A population-based cohort study. J Gerontol A Biol Sci Med Sci. 2018;73(11):1538–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.